Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    The feasibility and efficacy of subcutaneous and intravenous Plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA–identical sibling donors: a randomized phase II study.

    Summary
    EudraCT number
    2010-023436-16
    Trial protocol
    NL   DE  
    Global end of trial date
    28 Jan 2019

    Results information
    Results version number
    v1(current)
    This version publication date
    18 Jul 2024
    First version publication date
    18 Jul 2024
    Other versions
    Summary report(s)
    HO107_End of trial report_17Jun2020

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    HOVON 107
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    HOVON
    Sponsor organisation address
    Dr. Molenwaterplein 40, Rotterdam, Netherlands,
    Public contact
    HOVON, HOVON, hovon@erasmusmc.nl
    Scientific contact
    HOVON, HOVON, hovon@erasmusmc.nl
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    14 Aug 2017
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    14 Jun 2017
    Global end of trial reached?
    Yes
    Global end of trial date
    28 Jan 2019
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To determine the feasibility of plerixafor 320 μg/kg subcutaneously and of plerixafor 320 μg/kg intravenously to harvest a sufficient number of CD34+ peripheral blood stem cells/kg recipient body weight. Feasibilty is defined as a minimum of 2.0x106/kg CD34+ cells in one or two phereses in at least 90% of the donors
    Protection of trial subjects
    Monitoring and Insurance
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    31 May 2011
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Netherlands: 70
    Country: Number of subjects enrolled
    Germany: 6
    Worldwide total number of subjects
    76
    EEA total number of subjects
    76
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    75
    From 65 to 84 years
    1
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    All subjects gave written informed consent and were screened according to the inclusion- and exclusion criteria.

    Period 1
    Period 1 title
    Overall period
    Is this the baseline period?
    Yes
    Allocation method
    Non-randomised - controlled
    Blinding used
    Not blinded

    Arms
    Arm title
    Experimental group
    Arm description
    -
    Arm type
    Experimental

    Investigational medicinal product name
    Plerixafor
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Injection
    Dosage and administration details
    Plerixafor 320 μg/kg subcutaneously

    Number of subjects in period 1
    Experimental group
    Started
    76
    Completed
    70
    Not completed
    6
         Adverse events, all combined
    1
         Other
    2
         Lack of efficacy
    3

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Overall period
    Reporting group description
    -

    Reporting group values
    Overall period Total
    Number of subjects
    76 76
    Age categorical
    Units: Subjects
        In utero
    0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0
        Newborns (0-27 days)
    0 0
        Infants and toddlers (28 days-23 months)
    0 0
        Children (2-11 years)
    0 0
        Adolescents (12-17 years)
    0 0
        Adults (18-64 years)
    75 75
        From 65-84 years
    1 1
        85 years and over
    0 0
    Age continuous
    Units: years
        median (full range (min-max))
    49 (21 to 65) -
    Gender categorical
    Units: Subjects
        Female
    28 28
        Male
    48 48

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Experimental group
    Reporting group description
    -

    Primary: Primary endpoint

    Close Top of page
    End point title
    Primary endpoint [1]
    End point description
    End point type
    Primary
    End point timeframe
    See publication
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: See publication
    End point values
    Experimental group
    Number of subjects analysed
    76
    Units: Whole
    76
    Attachments
    Untitled (Filename: nonsaedata107-6May2024.pdf)
    Untitled (Filename: saedata107-6May2024.pdf)
    Untitled (Filename: HO107 Statistics (1).pdf)
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Adverse events will be reported from the first study-related procedure until 30 days following the last dose of any drug from the protocol treatment schedule or until the start of subsequent systemic therapy for the disease under study, if earlier.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    CTCAE
    Dictionary version
    4
    Reporting groups
    Reporting group title
    Experimental group
    Reporting group description
    -

    Serious adverse events
    Experimental group
    Total subjects affected by serious adverse events
         subjects affected / exposed
    6 / 74 (8.11%)
         number of deaths (all causes)
    15
         number of deaths resulting from adverse events
    Blood and lymphatic system disorders
    Clotting during stem cell apheresis
         subjects affected / exposed
    2 / 74 (2.70%)
         occurrences causally related to treatment / all
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    General disorders and administration site conditions
    Fever
         subjects affected / exposed
    1 / 74 (1.35%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Renal and urinary disorders
    Renal dysfunction
         subjects affected / exposed
    1 / 74 (1.35%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Infections and infestations
    Chronic kidney disease
         subjects affected / exposed
    1 / 74 (1.35%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Sepsis
         subjects affected / exposed
    1 / 74 (1.35%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Sepsis, acute kidney failure and respiratory failure
         subjects affected / exposed
    1 / 74 (1.35%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Metabolism and nutrition disorders
    Hypokalemia
         subjects affected / exposed
    1 / 74 (1.35%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 0%
    Non-serious adverse events
    Experimental group
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    45 / 74 (60.81%)
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Neoplasms bening, malignant and unspecified
    Additional description: All combined
         subjects affected / exposed
    1 / 74 (1.35%)
         occurrences all number
    1
    Vascular disorders
    Vascular disorders
    Additional description: All combined
         subjects affected / exposed
    8 / 74 (10.81%)
         occurrences all number
    8
    General disorders and administration site conditions
    General disorders and administration site conditions
    Additional description: All combined
         subjects affected / exposed
    14 / 74 (18.92%)
         occurrences all number
    15
    Immune system disorders
    Immune system disorders
    Additional description: All combined
         subjects affected / exposed
    2 / 74 (2.70%)
         occurrences all number
    2
    Respiratory, thoracic and mediastinal disorders
    Respiratory, thoracic and mediastinal disorders
    Additional description: All combined
         subjects affected / exposed
    4 / 74 (5.41%)
         occurrences all number
    4
    Psychiatric disorders
    Psychiatric disorders
         subjects affected / exposed
    1 / 74 (1.35%)
         occurrences all number
    1
    Investigations
    Investigations
    Additional description: All combined
         subjects affected / exposed
    11 / 74 (14.86%)
         occurrences all number
    25
    Injury, poisoning and procedural complications
    Injury, poisoning and procedural complications
    Additional description: All combined
         subjects affected / exposed
    3 / 74 (4.05%)
         occurrences all number
    5
    Cardiac disorders
    Cardiac disorders
    Additional description: All combined
         subjects affected / exposed
    1 / 74 (1.35%)
         occurrences all number
    1
    Nervous system disorders
    Nervous system disorders
    Additional description: All combined
         subjects affected / exposed
    13 / 74 (17.57%)
         occurrences all number
    18
    Blood and lymphatic system disorders
    Blood and lymphatic system disorders
    Additional description: All combined
         subjects affected / exposed
    6 / 74 (8.11%)
         occurrences all number
    8
    Gastrointestinal disorders
    Gastrointestinal disorders
    Additional description: All combined
         subjects affected / exposed
    22 / 74 (29.73%)
         occurrences all number
    31
    Hepatobiliary disorders
    Hepatobiliary disorders
    Additional description: All combined
         subjects affected / exposed
    1 / 74 (1.35%)
         occurrences all number
    2
    Skin and subcutaneous tissue disorders
    Skin and subcutaneous tissue disorders
    Additional description: All combined
         subjects affected / exposed
    2 / 74 (2.70%)
         occurrences all number
    2
    Renal and urinary disorders
    Renal and urinary disorders
    Additional description: All combined
         subjects affected / exposed
    2 / 74 (2.70%)
         occurrences all number
    2
    Musculoskeletal and connective tissue disorders
    Musculoskeletal and connective tissue disorders
    Additional description: All combined
         subjects affected / exposed
    4 / 74 (5.41%)
         occurrences all number
    4
    Infections and infestations
    Infections and infestations
    Additional description: All combined
         subjects affected / exposed
    9 / 74 (12.16%)
         occurrences all number
    10
    Metabolism and nutrition disorders
    Metabolism and nutrition disorders
    Additional description: All combined
         subjects affected / exposed
    3 / 74 (4.05%)
         occurrences all number
    4

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    19 Mar 2012
    adding a new investigational drug; an essential change to the current investigational medicinal product other, namely: Change in protocol inclusion criteria for patients and some typographical errors"
    25 Sep 2013
    new document for product information cell therapy product, change type of product information on EudraCT form to SmPC, SmPC plerixafor NL, administrative changes to protocol, change of address of the HDC due to relocation and change of independent doctor VUMC.
    14 May 2014
    adding safety information about plerixafor and prevention of pregnancy (period of contraceptive use has been extended to 3 months after the last dose of plerixafor), adjustment of patient exclusion criteria, administrative changes to protocol and information letters for test subjects, change to coordinating researcher VUmc.
    27 Nov 2014
    clarification of the advice on how to act if the harvest of CD34+ cells is too low.
    28 Apr 2015
    modification of the protocol and associated study documents in which the intravenous arm is closed and only the subcutaneous arm is continued. This means that approximately 15 donors/patients still need to be included with an expected duration of 1.5-2 years.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported

    Online references

    http://www.ncbi.nlm.nih.gov/pubmed/30548284
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 01:59:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA